Kinji Fuchikami
Directeur/Membre du Conseil chez NapaJen Pharma, Inc.
Profil
Mr. Kinji Fuchikami is Venture Partner at MVC Corp.
He comes with over 10 years of experience in drug discovery researches from gene discovery to preclinical research.
Prior to joining MVC, he worked for 12 years at Research Center Kyoto, in Bayer Yakuhin, Ltd.
At Bayer, his primary focus was kinase inhibitors, respiratory diseases, inflammatory diseases and allergy.
Mr. Fuchikami holds an M.Sc.
In the field of Medical Sciences from Osaka University Medical School.
Postes actifs de Kinji Fuchikami
| Sociétés | Poste | Début |
|---|---|---|
Mitsui & Co. Global Investment Ltd.
 Mitsui & Co. Global Investment Ltd. Investment ManagersFinance Mitsui & Co. Global Investment Ltd is a private Equity/venture Capital firm, a subsidiary of Mitsui & Co., Ltd. founded in 1996. The firm is headquartered in Tokyo. | Private Equity Investor | 01/12/2004 |
NapaJen Pharma, Inc.
 NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Directeur/Membre du Conseil | 22/04/2011 |
Anciens postes connus de Kinji Fuchikami
| Sociétés | Poste | Fin |
|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Directeur/Membre du Conseil | - |
Formation de Kinji Fuchikami
| Osaka University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Mitsui & Co. Global Investment Ltd.
Mitsui & Co. Global Investment Ltd. Investment ManagersFinance Mitsui & Co. Global Investment Ltd is a private Equity/venture Capital firm, a subsidiary of Mitsui & Co., Ltd. founded in 1996. The firm is headquartered in Tokyo. | Finance |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Health Technology |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
